Latest Content

The federal nod was given based from the phase 3 data of the EAGLE-1 trial, which showed noninferiority to combination therapy. This approval provides a new oral option.

NYU’s Angelica Cifuentes Kottkamp, MD, continues our Media Day discussion around these illnesses and how in New York City, clinicians need to be prepared to decipher in differential diagnosis for these potential diseases.

Reports are surfacing the federal agency is going to review products already reviewed and approved.

In episode 2 of our Media Day series with New York University (NYU), Angelica Cifuentes Kottkamp, MD, discusses its vaccine center and their work around COVID-19 vaccines, as well as the importance of achieving diversity in clinical trials.

Robert Hopkins Jr, MD, medical director of the National Foundation for Infectious Diseases, discusses the changes in the new vaccine recommendations and what potential serious consequences may be seen as a result.

The federal agency approved Augmentin XR in just 2 months through the new CNPV pilot program, marking a potential step toward rebuilding domestic antibiotic manufacturing and addressing drug shortages.

Questions raised about unverified FDA claims linking COVID-19 vaccines to pediatric deaths, and concerns that proposed vaccine testing requirements could delay access to key immunizations.

A large meta-analysis indicates opioid exposure may disrupt immunity and gut microbiota, increasing CDI vulnerability and potentially worsening clinical outcomes.

Angelica Cifuentes Kottkamp, MD, discusses how its location, breadth of experience, and opportunities afford clinicians the ability to see and treat a wide berth of diseases and infections.

Population study corroborates 2019 FDA alert based on case reports of acute respiratory failure with TMP-SMX in healthy adolescents and young adults.

This week, read our coverage on the CDC ACIP meetings on the hepatitis B virus (HBV) vaccine, modeling data on the potential consequences of HBV infections, liver cancer, and mortality when delaying the birth dose to 2 months, our latest podcast, and more.

Lacking any safety data showing potential serious adverse effects, the committee decided to move forward with the recommendation “that the initial dose is administered no earlier than 2 months of age.”

Due to repetitive and confusing language, the committee decided to amend the votes for clarity and will vote on 3 new recommendations on Friday.